Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks MHRA Drug Safety Update
It is susceptible to carboxypeptidase cleavage, light-driven copper photo-oxidation and pH extremes, with an optimum of about 5.0 to 6.5
For microdosing, they may increase the dosage after 8-10 weeks
Key developments expected in the coming months include: Near-Term Milestones Bellwether Trial Selection Representative cases will be chosen for early trial Expert Testimony Medical experts will testify on causation and drug safety Document Discovery Internal company communications under review Looking Ahead Settlement Talks If bellwether trials favor plaintiffs, Novo Nordisk may negotiate global settlements MDL Expansion New claims involving hair loss, kidney injury, and emotional distress are being evaluated First Trials Expected to begin in early 2026 Legal analysts expect the first bellwether trials to begin in early 2026, potentially setting precedent for thousands of future claims
US$ 24.21
US$ 23.36
US$ 27.97
